{"id":"NCT01241240","sponsor":"Allergan","briefTitle":"Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension","officialTitle":null,"status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-03","primaryCompletion":"2013-09","completion":"2013-09","firstPosted":"2010-11-16","resultsPosted":"2014-09-10","lastUpdate":"2014-09-10"},"enrollment":192,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Glaucoma, Open-Angle","Ocular Hypertension"],"interventions":[{"type":"DRUG","name":"bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy)","otherNames":[]},{"type":"DRUG","name":"Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution","otherNames":["COMBIGAN®"]}],"arms":[{"label":"Triple Combination Therapy","type":"EXPERIMENTAL"},{"label":"Combigan®","type":"ACTIVE_COMPARATOR"}],"summary":"This study will evaluate the safety and efficacy of Triple Combination Therapy compared with Fixed Combination brimonidine tartrate/timolol ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension.","primaryOutcome":{"measure":"Change From Baseline in Mean Worse Eye Intraocular Pressure (IOP) at Week 12","timeFrame":"Baseline, Week 12","effectByArm":[{"arm":"Triple Combination Therapy","deltaMin":24.62,"sd":2.475},{"arm":"Combigan®","deltaMin":25.12,"sd":2.178}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":4},"locations":{"siteCount":2,"countries":["Colombia","Mexico"]},"refs":{"pmids":["29057117"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":93},"commonTop":["Conjunctival hyperaemia","Eye irritation","Somnolence","Dry eye","Visual field defect"]}}